Dysregulated modifications of Tau and/or mutations of MAPT underlie the pathogenesis of Tauopathy that includes Alzheimer’s disease, frontotemporal dementia, Pick’s disease, etc., making Tau a promising target for Tauopathy treatment [4–6]. This evidence concerns the gene MAPT and Alzheimer disease.